会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Piperdines for use as orexin receptor antagonists
    • 用作食欲肽受体拮抗剂的Pi子
    • US06677354B2
    • 2004-01-13
    • US10311445
    • 2002-12-16
    • Clive Leslie BranchChristopher Norbert JohnsonGeoffrey StempKevin Thewlis
    • Clive Leslie BranchChristopher Norbert JohnsonGeoffrey StempKevin Thewlis
    • A61K314545
    • C07D401/06C07D211/26C07D401/10C07D405/06C07D405/10C07D405/14C07D409/14C07D413/10C07D413/14C07D417/06C07D417/14C07D471/04
    • Disclosed are compounds of formula (I): wherein: Y represents a group (CH2)n, wherein n represents 0, 1 or 2; R1 is phenyl, naphthyl, a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S; or a group NR3R4 wherein one of R3 and R4 is hydrogen or optionally substituted (C1-4)alkyl and the other is phenyl, naphthyl or a mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S, or R3 and R4 together with the N atom to which they are attached form a 5 to 7-membered cyclic amine which has an optionally fused phenyl ring; any of which R1 groups may be optionally substituted; R2 represents phenyl or a 5- or 6-membered heteroaryl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heteroaryl group is substituted by R5, and further optional substituents; or R2 represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 3 heteroatoms selected from N, O and S; R5 represents an optionally substituted (C1-4)alkoxy, halo, optionally substituted (C1-6)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclic ring containing up to 3 heteroatoms selected from N, O and S; or pharmaceutically acceptable salts thereof.
    • 公开了式(I)的化合物:其中:Y表示基团(CH 2)n,其中n表示0,1或2; R 1是苯基,萘基,含有至多3个选自杂原子的单或双环杂芳基 来自N,O和S; 或NR 3或R 4基团,其中R 3和R 4中的一个是氢或任选取代的(C 1-4)烷基,另一个是苯基,萘基或含有上述的单或双环杂芳基 至3个选自N,O和S的杂原子,或R 3和R 4与它们所连接的N原子一起形成具有任选稠合的苯环的5至7元环胺; 任何R 1可以任选被取代; R 2表示苯基或含有至多3个选自N,O和S的杂原子的5-或6-元杂芳基,其中苯基或杂芳基被取代 R 5和另外任选的取代基; 或R 2表示含有至多3个选自N,O和S的杂原子的任选取代的双环芳族或双环杂芳族基团; R 5表示任选取代的(C 1-4)烷氧基,卤素,任选取代的(C1- 6)烷基,任选取代的苯基或含有至多3个选自N,O和S的杂原子的任选取代的5或6元杂环; 或其药学上可接受的盐。
    • 9. 发明授权
    • Benzoxazinone derivatives, their preparation and use
    • US06939871B2
    • 2005-09-06
    • US10415119
    • 2001-10-22
    • Christopher Norbert JohnsonHarshad Kantilal RamiGeoffrey StempKevin ThewlisMervyn ThompsonAntonio Keuok Keong Vong
    • Christopher Norbert JohnsonHarshad Kantilal RamiGeoffrey StempKevin ThewlisMervyn ThompsonAntonio Keuok Keong Vong
    • A61K31/538A61P25/00A61P25/22A61P25/24C07D413/12C07D413/14C07D413/10A61P25/18
    • C07D413/12C07D413/14
    • The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, naphthyl, a monocyclic heteroaromatic group or a bicyclic heteroaromatic group, said Ar group being optionally substituted by 1-4 substituents, which may be the same or different, and which are selected from the group consisting of: halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-6alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-6alkoxy, arylC1-6alkoxy, C1-6alkylthio, C1-6alkoxyC1-6-alkyl, C3-7cycloalkylC1-6alkoxy, C1-6alkanoyl, C1-6alkoxycarbonyl, C1-6alkylsulfonyl, C1-6alkylsulfinyl, C1-6alkylsulfonyloxy, C1-6alkylsulfonylC1-6alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC1-6alkyl, C1-6alkylsulfonamido, C1-6alkylamido, C1-6alkylsulfonamidoC1-6alkyl, C1-6alkylamidoC1-6alkyl, arylsulfonamido, arylcarboxamido, alkylsulfonamidoC1-6alkyl, arylcarboxamidoC1-6alkyl, aroyl, arolC1-6alkyl, arylC1-6alkanoyl, a group R OCO(CH2)s, R CON(R )(CH2)s, R R NCO(CH2)s or R R NSO2(CH2) where each of R and R independently represents a hydrogen atom or C1-4alkyl or R and R form part of a C3-6azacyloalkane or C3-6(2-oxo)azacycloalkane ring and s represents zero or an integer from 1 to 4, and a group Ar Z, wherein Z represents a single bond, O, S or CH2 and Ar represents a phenyl or a monocyclic heteroaromatic group, said Ar group being optionally substituted by 1-3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C1-6alkyl, C1-6alkoxy or C1-6alkanoyl; when Ar is a phenyl or a monocyclic heteroaromatic group, substitutents positioned ortho to one another may be linked to form a 5- or 6-membered ring; R is hydrogen, C1-6alkyl, C3-6alkenyl, C3-6alkynyl or arylC1-6alkyl; R is halogen, C1-6alkyl, cyano, CF3, C1-6alkanoyl, C1-6alkoxy or hydroxy; X is CH or N; Y is a single bond, O, or C═O; p is 0, 1 or 2; r is 0, 1, 2 or 3; m is 2, 3 or 4; n and q are independently 1 or 2. Processes for preparing the compounds, pharmaceutical compositions containing them and their use as medicaments for various CNS disorders, including deression and/or anxiety, are also disclosed.
    • 10. 发明申请
    • Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine
    • US20070270471A1
    • 2007-11-22
    • US11573366
    • 2005-08-05
    • Kevin ThewlisSimon Ward
    • Kevin ThewlisSimon Ward
    • A61K31/40A61K31/4439A61P25/18C07D207/14C07D401/10
    • C07D207/14C07D403/10C07D409/10
    • This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; B is —N(R4)— or —O—; A and D, which may be the same or different, are —C(R5)2—; each R2, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; n is 0, 1 or 2; R3 is C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, —(CH2)pNR3aSO2R3b, —(CH2)pNR3a(C═O)R3b, —(CH2)pNR3a(C═O)N(R3c)2, —(CH2)p(C═O)R3d, —(CH2)pSO2R3e, phenyl or heterocyclyl, wherein when R3 is phenyl or heterocyclyl, it is optionally substituted by one or more groups independently selected from: C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, —(CH2)pNR3aSO2R3b, —(CH2)pNR3a(C═O)R3b, —(CH2)pNR3a(C═O)N(R3c)2, —(CH2)p(C═O)R3d and —(CH2)pSO2R3e; where R3a and each R3c, which may be the same or different, is hydrogen or C1-6alkyl; R3b and R3e are C1-6alkyl or haloC1-6alkyl; R3d is C1-6alkyl, C1-4alkoxy or haloC1-6alkyl; or R3a and R3b, or R3a and R3c, together with the interconnecting atoms, may form a 5- or 6-membered ring; and p is 0, 1, or 2; R4 is carbocyclyl or carbocyclylC1-4alkyl, wherein the carbocyclyl group of either is optionally substituted by one or more groups independently selected from C1-6alkyl and halogen; or R4 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-6alkylcarbonyl, C1-6alkylsulfonyl or C1-6alkylaminocarbonyl; each R5, which may be the same or different, is hydrogen, C1-6alkyl or halogen; and R6 is hydrogen or fluorine.